KR20220108064A - 최적화된 gip 펩타이드 유사체 - Google Patents

최적화된 gip 펩타이드 유사체 Download PDF

Info

Publication number
KR20220108064A
KR20220108064A KR1020227018518A KR20227018518A KR20220108064A KR 20220108064 A KR20220108064 A KR 20220108064A KR 1020227018518 A KR1020227018518 A KR 1020227018518A KR 20227018518 A KR20227018518 A KR 20227018518A KR 20220108064 A KR20220108064 A KR 20220108064A
Authority
KR
South Korea
Prior art keywords
gip
seq
amino acid
peptide analog
cex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227018518A
Other languages
English (en)
Korean (ko)
Inventor
메트 마리 로센킬드
알렉산더 호바드 스파르-울리히
디트 리베르
삼라 요크 산니
Original Assignee
안타그 테라퓨틱스 에이피에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2019/083506 external-priority patent/WO2020115048A1/en
Application filed by 안타그 테라퓨틱스 에이피에스 filed Critical 안타그 테라퓨틱스 에이피에스
Publication of KR20220108064A publication Critical patent/KR20220108064A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020227018518A 2019-12-03 2020-12-03 최적화된 gip 펩타이드 유사체 Pending KR20220108064A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues
EPPCT/EP2019/083506 2019-12-03
EP20179259 2020-06-10
EP20179259.5 2020-06-10
PCT/EP2020/084487 WO2021110845A1 (en) 2019-12-03 2020-12-03 Optimized gip peptide analogues

Publications (1)

Publication Number Publication Date
KR20220108064A true KR20220108064A (ko) 2022-08-02

Family

ID=71083547

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018518A Pending KR20220108064A (ko) 2019-12-03 2020-12-03 최적화된 gip 펩타이드 유사체

Country Status (9)

Country Link
US (1) US20250346647A2 (https=)
EP (1) EP4069719A1 (https=)
JP (2) JP7788376B2 (https=)
KR (1) KR20220108064A (https=)
AU (1) AU2020398675A1 (https=)
CA (1) CA3157387A1 (https=)
IL (1) IL293249A (https=)
MX (1) MX2022006737A (https=)
WO (1) WO2021110845A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240021212A (ko) * 2021-06-10 2024-02-16 안타그 테라퓨틱스 에이피에스 비만 및 비만-관련 장애의 치료
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
UY40349A (es) * 2022-07-13 2024-01-31 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Agonista dual de glp-1/gip, método de preparación y uso del mismo
WO2025259957A1 (en) * 2024-06-14 2025-12-18 Eli Lilly And Company Compositions and methods for improving insulin sensitivity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0606992A2 (pt) * 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
AU2007284365A1 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
KR101417873B1 (ko) * 2008-08-07 2014-07-09 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 유사체
JP2011530507A (ja) * 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ グルコース依存性インスリン分泌刺激ポリペプチドアナログ
JP6228187B2 (ja) * 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
US10968266B2 (en) * 2014-09-05 2021-04-06 University Of Copenhagen GIP peptide analogues
PL3630806T3 (pl) * 2017-05-31 2024-05-13 The University Of Copenhagen Analogi peptydów gip o długotrwałym działaniu
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CN121449721A (zh) * 2018-12-03 2026-02-03 安泰博医药 经修饰的gip肽类似物

Also Published As

Publication number Publication date
WO2021110845A1 (en) 2021-06-10
EP4069719A1 (en) 2022-10-12
JP2023505441A (ja) 2023-02-09
CA3157387A1 (en) 2021-06-10
US20250346647A2 (en) 2025-11-13
IL293249A (en) 2022-07-01
JP2025172864A (ja) 2025-11-26
JP7788376B2 (ja) 2025-12-18
AU2020398675A1 (en) 2022-05-26
CN114761420A (zh) 2022-07-15
US20230416330A1 (en) 2023-12-28
MX2022006737A (es) 2022-06-14

Similar Documents

Publication Publication Date Title
US20250376499A1 (en) Modified gip peptide analogues
KR102351313B1 (ko) Gip/glp1 공효능제 화합물
CN111491658A (zh) 肠促胰岛素类似物及其用途
JP7788376B2 (ja) 最適化されたｇｉｐペプチド類縁体
KR20240093737A (ko) 단백질 타이로신-타이로신 유사체 및 그의 사용 방법
US11572399B2 (en) Long-acting GIP peptide analogues
RU2858286C2 (ru) Оптимизированные пептидные аналоги gip
CN114761420B (zh) 优化的gip肽类似物
RU2817673C2 (ru) Модифицированные аналоги GIP пептида
EA048422B1 (ru) Соединения-коагонисты gip/glp1

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000